O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) decreases levels of serum corticosterone, TNF-α, IL-1β, and IL-6[1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) increases hippocampal GPR55 protein expression [1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) significantly increases DCX expression in the DG [1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) significantly decreases the number of microglia in the hippocampus [1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) increases expression levels of NLRP3, ASC, and Caspase-1 in the hippocampus [1].
O-1602 (0.1 mg/kg,ip; subchronically infused for 7 days) decreases the percentage of fat utilization over total energy consumption and decreases metabolic use of lipids leading to elevated fat deposition rates[2].
O-1602 (0.04 and 0.4 μg/h/rat, ip; for 7 days) increases the the amount of fat mass with O-1602 at the dose of 0.4 μg/h/rat[2].
| Animal Model: | the model of METH-induced anxiety- and depression-like behaviors [1] |
| Dosage: | 10 mg/kg, once daily for 14 consecutive days |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Increased both time spent in the center area of the open field test and time exploring the open arms in the elevated plus maze test.
Reduced immobility time in the forced swim and tail suspension tests. |
| Animal Model: | Adult male Sprague–Dawley rats (Harlam Iberica, Barcelona, Spain) (250–275 g, 10–12 weeks old)[2] |
| Dosage: | 0.1, 0.5 and 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Did not modify food intake and body weight gain.Increased the fat mass. |
